These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27966948)

  • 1. Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
    Nara H; Kaieda A; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2017 Jan; 60(2):608-626. PubMed ID: 27966948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
    Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
    J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.
    Baragi VM; Becher G; Bendele AM; Biesinger R; Bluhm H; Boer J; Deng H; Dodd R; Essers M; Feuerstein T; Gallagher BM; Gege C; Hochgürtel M; Hofmann M; Jaworski A; Jin L; Kiely A; Korniski B; Kroth H; Nix D; Nolte B; Piecha D; Powers TS; Richter F; Schneider M; Steeneck C; Sucholeiki I; Taveras A; Timmermann A; Van Veldhuizen J; Weik J; Wu X; Xia B
    Arthritis Rheum; 2009 Jul; 60(7):2008-18. PubMed ID: 19565489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
    Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
    Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
    Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
    J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand Efficiencies.
    Fischer T; Riedl R
    Int J Mol Sci; 2016 Mar; 17(3):314. PubMed ID: 26938528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic characterization of 4,4'-biphenylsulfonamides as selective non-zinc binding MMP inhibitors.
    Santamaria S; Nuti E; Cercignani G; La Regina G; Silvestri R; Supuran CT; Rossello A
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):947-54. PubMed ID: 25694065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
    Di Pizio A; Agamennone M; Tortorella P
    Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
    Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
    J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a putative Zn
    Fuerst R; Choi JY; Knapinska AM; Cameron MD; Ruiz C; Delmas A; Sundrud MS; Fields GB; Roush WR
    Bioorg Med Chem Lett; 2022 Nov; 76():129014. PubMed ID: 36202189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.